Literature DB >> 24317308

Innovation in therapeutics development at the NCATS.

Christine M Colvis1, Christopher P Austin.   

Abstract

Mesh：

Year:  2014        PMID： 24317308      PMCID： PMC3857672          DOI： 10.1038/npp.2013.247

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  5 in total

Review 1.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  Translating discoveries into medicine: psychiatric drug development in 2011.

Authors:  Linda S Brady; Thomas R Insel
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

Review 3.  Diagnosing the decline in pharmaceutical R&D efficiency.

Authors:  Jack W Scannell; Alex Blanckley; Helen Boldon; Brian Warrington
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

4.  Mining for therapeutic gold.

Authors:  Francis S Collins
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

5.  Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial.

Authors:  Jeffrey M Statland; Brian N Bundy; Yunxia Wang; Dipa Raja Rayan; Jaya R Trivedi; Valeria A Sansone; Mohammad K Salajegheh; Shannon L Venance; Emma Ciafaloni; Emma Matthews; Giovanni Meola; Laura Herbelin; Robert C Griggs; Richard J Barohn; Michael G Hanna
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272
  5 in total
  7 in total

1.  The Rescue and Repurposing of Pharmaceuticals: Augmenting the Drug Development Paradigm.

Authors:  Michael D Reed
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

Review 2.  Facilitating the commercialization and use of organ platforms generated by the microphysiological systems (Tissue Chip) program through public-private partnerships.

Authors:  Christine A Livingston; Kristin M Fabre; Danilo A Tagle
Journal:  Comput Struct Biotechnol J       Date:  2016-05-10       Impact factor: 7.271

3.  The price of progress: Funding and financing Alzheimer's disease drug development.

Authors:  Jeffrey Cummings; Carl Reiber; Parvesh Kumar
Journal:  Alzheimers Dement (N Y)       Date:  2018-06-13

Review 4.  Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.

Authors:  Jeffrey Cummings; Aaron Ritter; Kate Zhong
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Predicting translational progress in biomedical research.

Authors:  B Ian Hutchins; Matthew T Davis; Rebecca A Meseroll; George M Santangelo
Journal:  PLoS Biol       Date:  2019-10-10       Impact factor: 8.029

6.  The future of translational research on alcohol use disorder.

Authors:  Lara A Ray; Erica N Grodin; Lorenzo Leggio; Anita J Bechtholt; Howard Becker; Sarah W Feldstein Ewing; James David Jentsch; Andrea C King; Barbara J Mason; Stephanie O'Malley; James MacKillop; Markus Heilig; George F Koob
Journal:  Addict Biol       Date:  2020-04-14       Impact factor: 4.280

7.  A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research.

Authors:  Gergely Zahoránszky-Kőhalmi; Vishal B Siramshetty; Praveen Kumar; Manideep Gurumurthy; Busola Grillo; Biju Mathew; Dimitrios Metaxatos; Mark Backus; Tim Mierzwa; Reid Simon; Ivan Grishagin; Laura Brovold; Ewy A Mathé; Matthew D Hall; Samuel G Michael; Alexander G Godfrey; Jordi Mestres; Lars J Jensen; Tudor I Oprea
Journal:  bioRxiv       Date:  2020-11-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.